Filter Results:
(1,274)
Show Results For
- All HBS Web
(1,274)
- People (4)
- News (228)
- Research (897)
- Events (4)
- Multimedia (7)
- Faculty Publications (489)
Show Results For
- All HBS Web
(1,274)
- People (4)
- News (228)
- Research (897)
- Events (4)
- Multimedia (7)
- Faculty Publications (489)
Page 1 of 1,274
Results →
- January 2021
- Case
Takeda Pharmaceutical Company Limited (A)
By: David J. Collis, Nobuo Sato and Akiko Kanno
This case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition would turn... View Details
Keywords: Pharmaceutical Companies; Pharmaceuticals; Biotech; Biotechnology; M＆A; Mergers ＆ Acquisitions; R＆D; Talent Management; Mergers and Acquisitions; Globalization; Management; Global Strategy; Talent and Talent Management; Pharmaceutical Industry; Pharmaceutical Industry; Japan; Asia
Collis, David J., Nobuo Sato, and Akiko Kanno. "Takeda Pharmaceutical Company Limited (A)." Harvard Business School Case 721-373, January 2021.
- January 2021
- Supplement
Takeda Pharmaceutical Company Limited (B)
By: David J. Collis, Nobuo Sato and Akiko Kanno
This case is a follow up to HBS Case No. 721-373, Takeda Pharmaceutical Company Limited (A). Following the events of the previous case, Takeda reached an agreement to acquire Ireland-based Shire Plc. The case follows some of the achievements and challenges Takeda and... View Details
Keywords: Pharmaceutical Companies; Pharmaceuticals; M＆A; Mergers ＆ Acquisitions; Biotech; Biotechnology; R＆D; Talent Management; Mergers and Acquisitions; Globalization; Global Strategy; Talent and Talent Management; Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Japan; Asia
Collis, David J., Nobuo Sato, and Akiko Kanno. "Takeda Pharmaceutical Company Limited (B)." Harvard Business School Supplement 721-374, January 2021.
- Article
Governments as Owners: State-Owned Multinational Companies
By: Alvaro Cuervo-Cazurra, Andrew Inkpen, Aldo Musacchio and Kannan Ramaswamy
The globalization of state-owned multinational companies (SOMNCs) has become an important phenomenon in international business (IB), yet it has received scant attention in the literature. We explain how the analysis of SOMNCs can help advance the literature by... View Details
Keywords: Multinational Corporation; State-owned Enterprises; State Capitalism; FDI; Internationalization; Government And Business; National Oil Companies; State Ownership; Multinational Firms and Management; Business Subsidiaries; Acquisition; Pharmaceutical Industry; Pharmaceutical Industry; China; India; Europe
Cuervo-Cazurra, Alvaro, Andrew Inkpen, Aldo Musacchio, and Kannan Ramaswamy. "Governments as Owners: State-Owned Multinational Companies." Special Issue on Governments as Owners: Globalizing State-Owned Enterprises edited by Alvaro Cuervo-Cazurra, Andrew Inkpen, Aldo Musacchio and Kannan Ramaswamy. Journal of International Business Studies 45, no. 8 (October–November 2014): 919–942.
- November 2012
- Supplement
Amylin Pharmaceuticals (B)
By: Richard G. Hamermesh and Carin-Isabel Knoop
Amylin Pharmaceuticals brought two first-in-class diabetes drugs to market, Byetta and Symlin, in 2005, which were sold in over 80 countries with $650.7 million in sales by 2011. However, the company remained unprofitable as sales plateaued. The small pharmaceutical... View Details
Keywords: Pharmaceuticals; Bristol-Myers Squibb; Health Care and Treatment; Pharmaceutical Industry; United States
Hamermesh, Richard G., and Carin-Isabel Knoop. "Amylin Pharmaceuticals (B)." Harvard Business School Supplement 813-091, November 2012.
- August 1983
- Case
CIBA-GEIGY Pharmaceuticals Division: Multinational Strategic Planning
Buzzell, Robert D. "CIBA-GEIGY Pharmaceuticals Division: Multinational Strategic Planning." Harvard Business School Case 584-018, August 1983.
- 2023
- Working Paper
Scoring and Funding Breakthrough Ideas: Evidence from a Global Pharmaceutical Company
By: Joshua Krieger, Ramana Nanda, Ian Hunt, Aimee Reynolds and Peter Tarsa
We study resource allocation to early-stage ideas at an internal startup program of
one the largest pharmaceutical firms in the world. Our research design enables us to
elicit every evaluator’s scores across five different attributes, before seeing how they
would... View Details
Keywords: Project Selection; Pharmaceuticals; Financing Innovation; Resource Allocation; Innovation and Invention; Research and Development
Krieger, Joshua, Ramana Nanda, Ian Hunt, Aimee Reynolds, and Peter Tarsa. "Scoring and Funding Breakthrough Ideas: Evidence from a Global Pharmaceutical Company." Harvard Business School Working Paper, No. 23-014, August 2022. (Revised November 2023.)
- Fast Answer
Screening: Multinational Companies
How do I screen for companies headquartered in one country or region with revenue or offices in another country or region? Capital IQ Hover over the Screening tab menu and select Companies. Under Company... View Details
- 1998
- Book
The Multinational Traders
By: Geoffrey Jones
This book examines the history and theory of multinational trading companies. The essays in this volume demonstrate the importance of trading companies in trade and investment flows in the world economy from the nineteenth century to the present day. The empirical... View Details
Keywords: Company History; Trade; Globalization; Books; Organizational Structure; Perspective; Diversification; Theory; Asia; Europe; United States
Jones, Geoffrey, ed. The Multinational Traders. Routledge International Studies in Business History. London: Routledge, 1998.
- February 2018 (Revised October 2024)
- Case
Hikma Pharmaceuticals Governance Journey
By: Lynn Paine, Suraj Srinivasan and Gamze Yucaoglu
The case opens with Said Darwazah, chairman and CEO of Hikma Pharmaceuticals, the multinational generics company, anticipating the company’s 2017 AGM and reflecting on changes made over the previous year to address concerns expressed by proxy advisors and some... View Details
Keywords: Boards Of Directors; Pharmaceuticals; Remuneration; Shareholder Engagement; Corporate Governance; Governing and Advisory Boards; Business and Shareholder Relations; Executive Compensation; Business Growth and Maturation; Emerging Markets; Private Sector; For-Profit Firms; Pharmaceutical Industry; Jordan
Paine, Lynn, Suraj Srinivasan, and Gamze Yucaoglu. "Hikma Pharmaceuticals Governance Journey." Harvard Business School Case 318-108, February 2018. (Revised October 2024.)
- November 1983
- Teaching Note
CIBA-GEIGY Pharmaceuticals Division: Multinational Strategic Planning, Teaching Note
By: Robert D. Buzzell
- March 2023
- Teaching Note
Hikma Pharmaceuticals Governance Journey
By: Suraj Srinivasan and Jonah Goldberg
Teaching Note for HBS Case No. 318108. The case opens with Said Darwazah, chairman and CEO of Hikma Pharmaceuticals, the multinational generics company, anticipating the company’s 2017 AGM and reflecting on changes made over the previous year to address concerns... View Details
Keywords: Jordan; Emerging Market; Private Sector; For-profit Firms; Boards Of Directors; Pharmaceuticals; Remuneration; Shareholder Engagement; Corporate Governance; Governing and Advisory Boards; Business and Shareholder Relations; Executive Compensation; Business Growth and Maturation; Pharmaceutical Industry; Jordan
- 1995
- Chapter
Pharmaceutical Companies and Health Care Reform
By: Arthur A. Daemmrich
- 2021
- Working Paper
Accounting for Product Impact in the Pharmaceuticals Industry
By: Amanda Rischbieth, George Serafeim and Katie Trinh
We apply the product impact measurement framework of the Impact-Weighted Accounts Initiative (IWAI) in two competitor companies within the pharmaceuticals industry. We design a monetization methodology that allows us to calculate monetary impact estimates of accessible... View Details
Keywords: Product Innovation; Impact; Impact Investing; Impact Measurement; ESG; ESG (Environmental, Social, Governance) Performance; ESG Ratings; Social Corporate Responsibility; Corporate Social Responsibility; Social Impact; Pharmaceutical Companies; Pharmaceuticals; IWAI; Product Design; Product Positioning; Society; Environmental Sustainability; Corporate Social Responsibility and Impact; Product; Safety; Pharmaceutical Industry
Rischbieth, Amanda, George Serafeim, and Katie Trinh. "Accounting for Product Impact in the Pharmaceuticals Industry." Harvard Business School Working Paper, No. 21-139, June 2021.
- November 1997 (Revised November 2010)
- Case
Hikma Pharmaceuticals (A)
By: John A. Quelch
The president of a Jordanian pharmaceutical company is contemplating how to further penetrate the U.S. market, either through its own manufacturing and sales efforts, or as a supplier to a third party. View Details
Keywords: Entrepreneurship; Globalized Markets and Industries; Emerging Markets; Expansion; Pharmaceutical Industry; Jordan; United States
Quelch, John A., and Robin Root. "Hikma Pharmaceuticals (A)." Harvard Business School Case 598-019, November 1997. (Revised November 2010.)
- September 2017
- Case
Dr. William Carson— Intrapreneurial Innovation in the Pharmaceutical Industry
By: Steven Rogers and Alyssa Haywoode
Dr. William Carson, an African-American alum of Harvard University became the President and CEO of a multi billion dollar division of Otsuka, a Japan based pharmaceutical company. His ascension to this leadership position followed a thriving career in academic medicine... View Details
Keywords: Dr. Williams Carson; Otsuka America Pharmaceutical; Harvard; Abilify; Aripiprazole; Health Testing and Trials; Globalized Firms and Management; Globalized Markets and Industries; Cross-Cultural and Cross-Border Issues; Decision Choices and Conditions; Pharmaceutical Industry; Japan
Rogers, Steven, and Alyssa Haywoode. "Dr. William Carson— Intrapreneurial Innovation in the Pharmaceutical Industry." Harvard Business School Case 318-005, September 2017.
- 2019
- Article
Pay-for-Monopoly?: An Assessment of Reverse Payment Deals by Pharmaceutical Companies
By: Sana Rafiq and Max Bazerman
Abstract
Over the past eighteen years, pharmaceutical firms have developed a blueprint to impede competition in order
to maintain their monopoly profits. This scheme, termed pay-for-delay, involves direct or indirect payment of
money from a branded-drug manufacturer... View Details
Rafiq, Sana, and Max Bazerman. "Pay-for-Monopoly? An Assessment of Reverse Payment Deals by Pharmaceutical Companies." Journal of Behavioral Economics for Policy 3, no. 1 (2019): 37–43.
- 2009
- Book
Merchants to Multinationals
By: G. Jones
Merchants to Multinationals examines the evolution of multinational trading companies from the eighteenth century to the present day. During the Industrial Revolution, British merchants established overseas branches which became major trade intermediaries and... View Details
- December 2020
- Article
Unwanted Attention: Swiss Multinationals and the Creation of International Corporate Guidelines in the 1970s
By: Sabine Pitteloud
During the last decade, we have seen an increased opposition to globalization. Within this wave of criticism, firms and more specifically multinational corporations have been major targets, accused of multiple wrongdoings, such as social dumping, fiscal evasion, job... View Details
Keywords: Multinationals; Guidelines; Lobbying; Business History; Multinational Firms and Management; Governing Rules, Regulations, and Reforms; Global Range; Switzerland
Pitteloud, Sabine. "Unwanted Attention: Swiss Multinationals and the Creation of International Corporate Guidelines in the 1970s." Special Issue on Multinational Corporations and the Politics of International Trade. Business and Politics 22, no. 4 (December 2020).